CoChat
Sign Up
Cited by 191Parkinson's Disease Mechanisms and TreatmentsTreatment of Major DepressionNeurological disorders and treatments

Antidepressant studies in Parkinson's disease: A review and meta‐analysis

Open access
Weintraub, Daniel, Morales, Knashawn H., Moberg, Paul J., Bilker, Warren B., Balderston, Catherine, Duda, John E., Katz, Ira R., Stern, Matthew B.·2005·Movement Disorders
DOI 10.1002/mds.20555PMC PMC1989731
Open this paper in CoChat — free account

Abstract

The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.20555

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacological treatments for depression and anxiety appear relatively ineffective in Parkinson's disease.

    “Pharmacological treatments for these conditions appear relatively ineffective in Parkinson’s disease.”

    From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [5]

    The Discussion (page not available in our copy) reports a large improvement with antidepressants for depression in Parkinson’s disease, but no advantage over placebo, supporting the claim only in the sense of limited medication-specific benefit. The paper does not assess pharmacological treatment for anxiety, so that part of the claim is unsupported. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • People with Parkinson's disease benefit less from antidepressant treatment than patients without Parkinson's disease.

    “people with PD benefit less from antidepressant treatment than do patients without PD [5]”

    From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [5]

    The Discussion says PD patients may benefit less from antidepressant treatment than elderly depressed patients without PD, and notes that diagnostic differences may partly explain the finding. The citing sentence states this as a fact and broadens the comparison beyond elderly depressed patients. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 76 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. [8]Poewe W, Luginger E. Depression in Parkinson’s disease. Neurology. 1999;52(Suppl):2–6. [PubMed] [Google Scholar]
  2. [19]Rosenthal R. Meta-analytic procedures for social research. Revised edition Sage Publications; Beverly Hills: 1984. [Google Scholar]
  3. [25]Cohen J. Statistical power analysis for the behavioral sciences. Academic Press; New York: 1977. [Google Scholar]
  4. [35]Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depression in patients with Parkinson’s disease. Curr Ther Res. 1990;48:154–160. [Google Scholar]
  5. [48]Meara RJ, Bhowmick BK, Hobson JP. An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson’s disease. J Serotonin Res. 1996;4:243–249. [Google Scholar]
  6. [59]Andersen J. Depressive tilstande bedømt ved rating scales. University of Copenhagen; Copenhagen: 1975. [Google Scholar]

Cited by

Sorted by citations

Related

Authors
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B.
Affiliations
  • Mental Illness Research, Education and Clinical Centers (US)
  • University of Pennsylvania (US)
  • Philadelphia VA Medical Center (US)
Corresponding author
Weintraub, Daniel
ORCID
Venue
Movement Disorders
Publisher
Wiley
Published
2005-06-13
Volume
20
Issue
9
Pages
1161-1169
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
DOI
10.1002/mds.20555
PMC
PMC1989731
OpenAlex
W2075843476
Cited by
191
References
76
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 5 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 8 · 2015: 9 · 2014: 8 · 2013: 10 · 2012: 14
FWCI
2.73
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Movement Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (K23MH067894, MH067894)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
Parkinson's disease, depression, antidepressants, selective serotonin reuptake inhibitors, placebo response, treatment response, elderly patients, major depressive disorder, age as predictor, antidepressant tolerability
MeSH terms
Antidepressive Agents, Humans, Parkinson Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review